Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2011
02/10/2011US20110034410 Wound dressing and method for controlling severe, life-threatening bleeding
02/10/2011US20110034409 Use of pharmaceutical compound in the treatment of wounds
02/10/2011US20110034408 High oil content o/w emulsions stabilized with a hydrophobically modified inulin and a hydrophilic acrylic polymer
02/10/2011US20110034407 Use of sphingomyelin and non-digestible carbohydrates for improving intestinal microbiota
02/10/2011US20110034405 Novel aminoglycoside antibiotics, process for producing the same, and pharmaceutical use thereof
02/10/2011US20110034403 use of ginsenoside rg1, its metabolites ginsenoside rh1 and/or ppt
02/10/2011US20110034402 C-aryl glycoside compounds for the treatment of diabetes and obesity
02/10/2011US20110034381 Methods for Therapeutic Treatment of Benign Prostatic Hypertrophy (BPH)
02/10/2011US20110034380 Combination of a selective ppar-gamma modulator and an incretin for the treatment of diabetes and obesity
02/10/2011US20110034379 Gastrin Compositions And Formulations, And Methods Of Use And Preparation
02/10/2011US20110034378 Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc.
02/10/2011US20110034375 Non-basic melanin concentrating hormone receptor-1 antagonists
02/10/2011US20110034370 Bis-met histones
02/10/2011US20110033595 Fatty acid fractionation process, fatty acid products and use thereof
02/10/2011US20110033566 Anti-bacterial composition comprising extract from barks of Alnus pendula Matsum
02/10/2011US20110033563 Stabilized Senna Extract Gel Formulation and Method of Preparation
02/10/2011US20110033561 Use of phytoecdysones in the preparation of a composition for acting on the metabolic syndrome
02/10/2011US20110033560 Preparation and a component intended to be added to a tobacco product
02/10/2011US20110033551 Nucleic acid microspheres, production and delivery thereof
02/10/2011US20110033550 Nanoparticle carriers for drug administration and process for producing same
02/10/2011US20110033548 Degradable crosslinked aminated dextran microspheres and methods of use
02/10/2011US20110033547 Dehydrated chitosan nanoparticles
02/10/2011US20110033545 Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
02/10/2011US20110033544 Intranasal pharmaceutical compositions with improved pharmacokinetcs
02/10/2011US20110033542 Sublingual and buccal film compositions
02/10/2011US20110033541 Sublingual and buccal film compositions
02/10/2011US20110033540 Polymer formulations for delivery of bioactive agents
02/10/2011US20110033539 Compositions and methods for preparing and using same
02/10/2011US20110033538 Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
02/10/2011US20110033537 Sustained Drug Release Composition
02/10/2011US20110033536 24-hour sustained-release metoclopramide
02/10/2011US20110033534 Controlled release tamsulosin hydrochloride tablets and a process of making them
02/10/2011US20110033533 Galenical formulations of organic compounds
02/10/2011US20110033531 Second Generation Fatty Acid Compositions, Formulations, and Methods of Use and Synthesis Thereof
02/10/2011US20110033529 Oral pharmaceutical paricalcitol formulations
02/10/2011US20110033528 Stabilized picoplatin oral dosage form
02/10/2011US20110033526 Pharmaceutical composition of antibiotics and prebiotics for preventing and treating dysbiosis during antibacterial therapy
02/10/2011US20110033525 Diterpene Glycosides as Natural Solubilizers
02/10/2011US20110033523 Use of microvesicles (mvs) derived from stem cells for preparing a medicament for endo/epithellal regeneration of damaged or injured tissues or organs, and related in vitro and in vivo methods
02/10/2011US20110033519 Device with Aromatase Inhibitor for the Treatment and Prevention of Uterine Fibroids and Method of Use
02/10/2011US20110033518 Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
02/10/2011US20110033508 Injectable microspheres for dermal augmentation and tissue bulking
02/10/2011US20110033506 Combination dosage form of low-dose modafinil and low-dose sildenafil
02/10/2011US20110033505 Methods and compositions for treatment of ion imbalances
02/10/2011US20110033503 Dressing compositions and methods
02/10/2011US20110033486 Gene expression markers for crohn's disease
02/10/2011US20110033482 Her3 as a determinant for the prognosis of melanoma
02/10/2011US20110033480 Methods and compositions involving nucleotide repeat disorders
02/10/2011US20110033475 Use of beta-glucans against biological warfare weapons and pathogens including anthrax
02/10/2011US20110033474 Inhibition of platelet aggregation
02/10/2011US20110033473 Anti influenza antibodies and uses thereof
02/10/2011US20110033469 Leukotriene b4 binding soluble lipocalin receptor from ixodes ricinus
02/10/2011US20110033468 Ophthalmic Drug Delivery System Containing Phospholipid and Cholesterol
02/10/2011US20110033466 Human transcriptomes
02/10/2011US20110033463 Apheresis, administration of agent, or combination thereof
02/10/2011US20110033461 Combination Therapy for the Treatment of Cancer
02/10/2011US20110033459 Combination therapy with a compound acting as a platelet adp receptor inhibitor
02/10/2011US20110033458 Combinations comprising epothilones and pharmaceutical uses thereof
02/10/2011US20110033457 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
02/10/2011US20110033453 Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
02/10/2011US20110033451 Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor
02/10/2011US20110033448 Inhibitors of LL-37 Mediated Immune Reactivity to Self Nucleic Acids
02/10/2011US20110033443 Method for Increasing Bone Mass
02/10/2011US20110033441 Pyrimidine derivatives for the treatment of abnormal cell growth
02/10/2011US20110033438 Method and pharmacological composition for the diagnosis and treatment of male
02/10/2011US20110033422 Treatments for flaviviridae virus infection
02/10/2011US20110033418 Treatment of diseases caused by viral infection
02/10/2011US20110033417 2,3-substituted indole derivatives for treating viral infections
02/10/2011US20110033414 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition
02/10/2011US20110033412 Compositions and methods for treating and preventing skeletal muscle deficiencies
02/10/2011US20110033406 Preserved product; and preservative composition
02/10/2011US20110033402 Solubilized benzoyl small molecule
02/10/2011US20110033395 Avermectin/metronidazole compositions for treating afflictions of the skin, e.g., rosacea
02/10/2011US20110033393 Hydrazone Compounds and Their Use
02/10/2011US20110033386 Method of detecting bladder cancer
02/10/2011US20110033384 Chimeric polypeptides and their use
02/10/2011US20110033376 Treatment of Melanoma
02/10/2011DE102009038512A1 Use of formulation comprising a substance, polyether polyol, preferably e.g. polyethylene glycol, dimethyl isosorbide, triglyceride, alcohol, preferably ethanol or isopropanol and residual water, to treat nail and/or nail bed disease
02/10/2011DE102009036646A1 Prasugrel in nicht-kristalliner Form und pharmazeutische Zusammensetzung davon Prasugrel in non-crystalline form and pharmaceutical composition thereof
02/10/2011DE102009034526A1 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten 17-hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynyl-phenyl derivatives, to processes for their preparation and their use for the treatment of diseases
02/10/2011CA2806295A1 Methods and compositions for treating insects
02/10/2011CA2805958A1 Greater utility with thyroid hormone
02/10/2011CA2805127A1 Process for preparation of over-the-counter gelatin or pectin-based drug delivery
02/10/2011CA2780829A1 Conformationally constrained, fully synthetic macrocyclic compounds
02/10/2011CA2775091A1 Controlled release pharmaceutical compositions of milnacipran
02/10/2011CA2771089A1 Sublingual and buccal film compositions
02/10/2011CA2770409A1 Nitrogenous-ring acylguanidine derivative
02/10/2011CA2770405A1 Sulfone derivative
02/10/2011CA2770404A1 Amide derivative
02/10/2011CA2770307A1 Compositions containing jarid1b inhibitors and methods for treating cancer
02/10/2011CA2770282A1 Composition and methods of treating viral infections and viral induced tumors
02/10/2011CA2770248A1 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators
02/10/2011CA2770195A1 Aminopyrazole derivative
02/10/2011CA2770194A1 Sphingosine-1-phosphate receptor agonists
02/10/2011CA2770180A1 Sublingual and buccal film compositions
02/10/2011CA2770156A1 Novel bicyclic urea compounds
02/10/2011CA2770155A1 Novel azaheterocyclic compounds
02/10/2011CA2770140A1 Antiviral compounds and methods of making and using thereof cross reference to related applications
02/10/2011CA2770100A1 Methods of using c-met modulators
02/10/2011CA2770092A1 Treatment of prostate cancer